Novavax (NASDAQ:NVAX) Climbs Early on Positive Influenza Vaccine Study Results

Shares of Novavax (NASDAQ:NVAX) are trading 5.6% higher to $2.47 premarket Wednesday after the company announced what it called positive results from Stage A of its two-stage study evaluating the safety and effectiveness of a pandemic influenza vaccine.

The data showed that safety and immunogenicity among the entire 1,000-person study population were consistent with preliminary results previously disclosed from the first 500 volunteers of Stage A, in which the vaccine was found to be well-tolerated and immunogenic at all three dose levels tested.